RxDoctor Payments Data

Didi Theva, MD

Urology · Fall River, MANPI 1740600295

Payments from drug & device makers

$4,982in general payments, 2019–2025

Across 49 payments — averaging $101.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Coloplast$827
  • Teleflex LLC$735
  • Boston Scientific$241
  • Dilon Technologies, Inc.$161
  • AbbVie$127
  • plus $336 from 6 others

What the payments were for

  • Consulting fees$1,32527%
  • Travel & lodging$66013%
  • Food & beverage$2,94759%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,982 in reported general payments places this provider in the 65th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$282,622
Medicare patients
634
Services billed
4,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron141$97,542
MyrbetriqMirabegron98$57,975
Estradiol197$12,352
Methenamine Hippurate147$9,694
Tamsulosin Hcl248$2,999
Oxybutynin Chloride ErOxybutynin Chloride131$2,839
Cefpodoxime Proxetil44$2,164
Solifenacin Succinate53$1,733
Finasteride96$1,362
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst164$1,229
Tolterodine Tartrate ErTolterodine Tartrate13$1,021
Terazosin Hcl16$445
Trospium Chloride18$429
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim133$318
Alfuzosin Hcl ErAlfuzosin Hcl12$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$91$57,97598 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 327 urology providers in Massachusetts.

Other urology in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →